Articles From: CTI BioPharma Announces Comprehensive Kinome Analysis that Demonstrates Pacritinib Inhibits Kinases Linked to a Spectrum of Blood-Related Cancers to AMC Networks to Participate in UBS Global Media and Communications Conference


-Profile Supports Potential Role in Modulating Tumor Microenvironment in Blood-Related Cancers, Including AML, MDS, CMML and CLL- -Analysis Also Provides Scientific Basis for Pacritinib's Lack of Myelosuppression, a Unique Attribute Among Agents in Development for Myelofibrosis- SEATTLE , Dec.
Sign-up for CTI BioPharma Announces Comprehensive Kinome Analysis that Demonstrates Pacritinib Inhibits Kinases Linked to a Spectrum of Blood-Related Cancers investment picks
Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today early study findings demonstrating that KEYTRUDA ® (pembrolizumab), the company’s anti-PD-1 therapy, achieved an overall response rate of 66 percent, as assessed by International Harmonization Project response criteria (n=19/29: 95% CI, 46-82), in transplant-ineligible and failure patients with relapsed/refractory classical Hodgkin Lymphoma (cHL) whose disease progressed on or after treatment with brentuximab vedotin.
Sign-up for Data Investigating KEYTRUDA® (pembrolizumab), Merck’s Anti-PD-1 Therapy, in Patients with Classical Hodgkin Lymphoma Presented at ASH Annual Meeting investment picks
http://media.marketwire.com/attachments/201211/99925_41732_threshold.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1163477&ProfileId=051205&sourceType=1 SAN FRANCISCO, CA --
Sign-up for Encouraging Initial Data From Ongoing Phase 1/2 Trial of TH-302 Plus Bortezomib (Velcade(R)) Plus Dexamethasone ("TBorD") in Patients With Relapsed/Refractory Multiple Myeloma Presented at ASH Annual Meeting investment picks
2014/12/6
UnitedHealthcare and the 4-H Youth Development Program at the University of Florida are expanding a successful partnership called Eat4-Health that helps tackle obesity by promoting healthy eating and active lifestyles among youth and families.
Sign-up for Florida 4-H and UnitedHealthcare Expand “Eat4-Health” Partnership, Use “Pedal Power” to Help Tackle Obesity and Encourage Healthy Lifestyles Among Youth investment picks
2014/12/6
- Note: This press release corresponds to abstract 31.
Sign-up for IMBRUVICA® (ibrutinib) Data Suggests Promise in Multiple Myeloma investment picks
93% (13/14) of evaluable CLL patients treated at dose levels ≥ 800mg of original formulation or any dose of the micronized formulation achieved a > 50% reduction in nodal size (a nodal PR) and 50% (7/14) achieved a partial response per iwCLL (Hallek 2008) criteria 100% (6/6) of CLL and iNHL patients achieving TGR-1202 drug concentrations above 4,000ng/ml responded at the first or second efficacy assessment with at least a nodal PR for CLL or PR for iNHL; Expansion cohorts now open at 800mg QD for CLL and 1200mg QD for iNHL, the dose level that appears to provide patients (3/3) with drug concentrations > 4,000ng/ml No drug related hepatic toxicity or colitis observed with 55 patients treated to date and median time on study of approximately 6 months and some patients on study for over 1.5 years TGR-1202 has been well-tolerated with no dose-related trends in adverse events observed and no MTD reached to date, dose escalation continues now at 1800mg QD SAN
Sign-up for Interim Data From Phase 1 Dose Escalation Clinical Trial of TGR-1202, the Once-Daily PI3K Delta Inhibitor, Demonstrates Significant Clinical Activity and Lack of Hepatic Toxicity in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphoma investment picks
http://media.marketwire.com/attachments/201211/54409_Methodelogo.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1163486&ProfileId=051205&sourceType=1 CHICAGO, IL --
Sign-up for Methode Electronics' Board Approves Dividend investment picks
Results Show Durable Responses in High Risk Patient Population MARTINSRIED, Germany , MUNICH and MONROVIA, Calif.
Sign-up for MorphoSys and Xencor Publish Final Results from Phase 1/2a Trial of MOR208 (XmAb5574) in CLL/SLL at ASH Annual Meeting investment picks
Seattle Genetics, Inc. (Nasdaq: SGEN) and Takeda Pharmaceutical Company Limited (TSE:4502) today reported data demonstrating that Hodgkin lymphoma (HL) patients at risk of relapse following an autologous stem cell transplant (ASCT) who received ADCETRIS (brentuximab vedotin) as consolidation therapy immediately after ASCT had significant improvement in progression-free survival (PFS) compared to patients who received placebo (median of 43 months versus 24 months, respectively; hazard ratio=0.57; p-value=0.001). The data from the AETHERA trial were featured at the 56th American Society of Hematology (ASH) Annual Meeting press program today and will be presented in an oral session on December 8, 2014.
Sign-up for Seattle Genetics and Takeda Report Phase 3 AETHERA Clinical Trial Data from ADCETRIS® (Brentuximab Vedotin) in Post-Transplant Hodgkin Lymphoma Patients at Risk of Relapse at ASH Annual Meeting investment picks
2014/12/6
Chipotle's Arnold says the chain has "a culture where employees are trained to make what they can with the ingredients we have if a customer asks." In other words, go ahead and enjoy your Quesarito.
Sign-up for UPDATE: 10 things Chipotle won't tell you -2- investment picks
2014/12/6
By Catey Hill, MarketWatch On special today: Old produce, big markups and hygiene problems 1.
Sign-up for UPDATE: 10 things grocery stores won't tell you investment picks
2014/12/6
By Amy Hoak, MarketWatch 'Smart home' gadgets become more affordable and more common Homeowners are increasingly looking to technology for home security solutions, to save on heating and cooling costs and even to help them cook the perfect steak.
Sign-up for UPDATE: 5 tech gadgets you need in your home today investment picks
A.M. Best has affirmed the financial strength rating of B+ (Good) and the issuer credit rating of “bbb-” of AES Global Insurance Company (AGIC) (Burlington, VT). The outlook for both ratings is stable.
Sign-up for A.M. Best Affirms Ratings of AES Global Insurance Company investment picks
2014/12/5
UNION CITY, Calif.
Sign-up for Abaxis, Inc. to Present at the Bank of America Merrill Lynch 2014 Animal & Dental Summit investment picks
2014/12/5
WILMINGTON, Del.
Sign-up for ACTUATE CORPORATION SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout investment picks
Shareholder Rights Law Firm Johnson & Weaver, LLP is investigating whether members of the board of directors of Actuate Corporation (NASDAQ: BIRT) breached their fiduciary duties in connection with the planned merger of the Company with OpenText Corporation.
Sign-up for ACTUATE SHAREHOLDER ALERT: Johnson & Weaver, LLP Investigates the Fairness of Price and Process in Proposed Sale of Actuate Corporation, Inc. to OpenText investment picks
Actuate Corporation (NASDAQ:BIRT), The BIRT Company™ and the leader in personalized analytics and insights, today announced that it has entered into an agreement to be acquired by OpenText.
Sign-up for Actuate Signs Agreement to be Acquired by OpenText investment picks
2014/12/5
SACRAMENTO, Calif., Dec.
Sign-up for Aerojet Rocketdyne Integral to Orion Crew Vehicle's Historic First Test Flight investment picks
Aethon, Inc. and BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today a collaboration to integrate their solutions to provide hospital pharmacies with a comprehensive intravenous medication preparation and delivery tracking solution.
Sign-up for Aethon and BD Announce Collaboration to Develop Integrated Medication Management Solution investment picks
BLOOMFIELD HILLS, Mich.
Sign-up for Agree Realty Announces Exercise of Underwriters' Option for Common Stock Offering investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=11G027908-001&sourceType=1 http://www.marketwire.com/library/MwGo/2014/12/5/11G027908/Logo1-1560415678.jpg LOS ANGELES, CA--(Marketwired - December 05, 2014) - Agritek Holdings, Inc. (OTCQB: AGTK) ( http://www.Agritekholdings.com ), a fully reporting company on the OTCQB and leader in Compassionate Care Technology and indoor/outdoor agricultural solutions for the medicinal marijuana industry, today announced that the Company has executed contracts with Blue Line Protection Group Inc. (OTCBB: BLPG) to provide security and transportation services on behalf of the Company's Colorado cultivation facility and campus located near Pueblo, Colorado.
Sign-up for Agritek Holdings, Inc. Announces Execution of Contract With Blue Line Protection Group for Colorado Cultivation Campus investment picks
2014/12/5
Latest Gift Brings Company's Total Contributions to $695,000 WASHINGTON , Dec.
Sign-up for Aimco Gives $130,000 for Scholarships for Students in Affordable Housing: investment picks
2014/12/5
Awarded 'Best Airline in North America ' for 10th time MONTREAL , Dec.
Sign-up for Air Canada Wins Multiple Travel Awards Affirming its Leadership Position among North American Carriers investment picks
LEHIGH VALLEY, Pa.
Sign-up for Air Products Supplies NASA Orion Launch Beginning New Era of Space Travel investment picks
Airgas, Inc. (NYSE: ARG) today announced that Andrew R.
Sign-up for Airgas Executive to Present at Bank of America Merrill Lynch 2014 U.S. Basic Materials Conference investment picks
Allegheny Technologies Incorporated (NYSE:ATI) announced today that its Board of Directors declared a quarterly cash dividend of $0.18 per share of common stock.
Sign-up for Allegheny Technologies Declares Quarterly Dividend investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0982745001&sourceType=1 http://media3.marketwire.com/docs/logo_ANV_200.jpg RENO, NEVADA --
Sign-up for Allied Nevada Provides Update on Recent Operational Developments investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: CTI BioPharma Announces Comprehensive Kinome Analysis that Demonstrates Pacritinib Inhibits Kinases Linked to a Spectrum of Blood-Related Cancers to AMC Networks to Participate in UBS Global Media and Communications Conference
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent